Type 2 Diabetes News and Research

Latest Type 2 Diabetes News and Research

Lilly, Boehringer Ingelheim announce availability of Jentadueto tablets

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company today announced Jentadueto (linagliptin/metformin hydrochloride) tablets are now available by prescription in many leading chain and independent pharmacies across the U.S.

8 Mar 2012

NCGR to host eighth annual NMBIST symposium on March 22-23, 2012

The National Center for Genome Resources (NCGR) announced today that it will host the eighth annual New Mexico Bioinformatics, Science and Technology (NMBIST) symposium on March 22-23, 2012.

7 Mar 2012

Study finds teenage girls sit or lie down for 19 hours a day

A study undertaken by UL researchers has found that teenage girls spend an average of 19 hours a day either sitting or lying down. Some 111 girls aged between 15 and 18 years took part in the study which measured the time they spent sitting, standing or lying down using a small accelerometer device. The researchers found that although total sitting and lying time was the same between weekdays and weekends, on week-days the sitting time was accumulated in longer bouts, lasting 20 minutes or more. These long bouts of sitting were more frequent during school time.

6 Mar 2012

Viewpoints: Statins and diabetes; Frightening tobacco warnings; The U.S. dental crisis

We're overdosing on cholesterol-lowering statins, and the consequence could be a sharp increase in the incidence of Type 2 diabetes. This past week, the Food and Drug Administration raised questions about the side effects of these drugs and developed new labels for these medications that will now warn of the risk of diabetes and memory loss.

6 Mar 2012

Nutrisystem 2011 revenues decrease to $401.3M

Nutrisystem, Inc., a leading provider of weight management products and services, today reported financial results for the year ended December 31, 2011.

5 Mar 2012

Nuvilex overcomes fundamental challenges faced in stem cell therapy

Nuvilex, Inc., an emerging biotechnology provider of cell and gene therapy solutions, released information today about the company's cell encapsulation technology and the breakthrough in stem cell research which overcomes specific fundamental challenges faced in stem cell therapy—host rejection and migration of implanted cells away from the target site.

5 Mar 2012

Concert commences dosing in CTP-499 Phase 2 clinical trial for diabetic nephropathy

Concert Pharmaceuticals, Inc. today announced the initiation of dosing in a Phase 2 clinical trial evaluating CTP-499, an investigational drug for the treatment of diabetic nephropathy, the leading cause of chronic kidney disease (CKD) in the US.

5 Mar 2012

Epicatechin-enriched cocoa shows promise against heart failure, Type 2 diabetes

A small clinical trial led by researchers at UC San Diego School of Medicine and VA San Diego Healthcare System (VASDHS) found that patients with advanced heart failure and type 2 diabetes showed improved mitochondrial structure after three months of treatment with epicatechin-enriched cocoa. Epicatechin is a flavonoid found in dark chocolate.

3 Mar 2012

AARDA hopes to educate public on autoimmune diseases during March

March is National Autoimmune Diseases Awareness Month, and the American Autoimmune Related Diseases Association (AARDA) is working to educate the public on risk factors, prevalence, and the severe lack of awareness surrounding autoimmune diseases.

3 Mar 2012

CLR01 blocks toxic aggregations of proteins in mouse model of Parkinson's

Millions of people suffer from Parkinson's disease, a disorder of the nervous system that affects movement and worsens over time. As the world's population ages, it's estimated that the number of people with the disease will rise sharply. Yet despite several effective therapies that treat Parkinson's symptoms, nothing slows its progression.

2 Mar 2012

Sedentary women more prone to developing type 2 diabetes

A new study has found that women who stay seated for long periods of time every day are more prone to developing type 2 diabetes, but that a similar link wasn't found in men.

2 Mar 2012

Ten physicians indicted in alleged $250 million fraud scheme

As has been the trend in some recent health care fraud cases, the physicians were not the ringmasters. Instead, the indictments allege that they were fronts for others - primarily immigrants from the former Soviet Union.

2 Mar 2012

Study uncovers how FoxO1 protein contributes to heart disease in patients with diabetes

UT Southwestern Medical Center cardiologists have uncovered how a specific protein's previously unsuspected role contributes to the deterioration of heart muscle in patients with diabetes. Investigators in the mouse study also have found a way to reverse the damage caused by this protein.

2 Mar 2012

Patients worried about statin use after label warnings from FDA

The U.S. Food and Drug Administration's announcement Tuesday stated that it would require additional safety warnings on the labels of the cholesterol-lowering drugs. Doctors have said that while the benefits of statins outweigh their potential harm, some patients are alarmed by the new announcement.

1 Mar 2012

FDA revises safety information on statin labels

The United States Food and Drug Administration (FDA) announced it is revising safety information on the labels of some statins (cholesterol lowering drugs).

1 Mar 2012

Statins to carry revised warning labels: FDA

The U.S. FDA announced today that they would add additional safety warnings to the labels on statins, a class of drugs that lower cholesterol. Statins – with brand names Lipitor, Crestor and Zocor work by inhibiting the enzyme that plays a big part in the liver's production of cholesterol.

29 Feb 2012

GI Dynamics reports revenues of US$234,000 for year ended 31 December 2011

GI Dynamics, Inc., a company pioneering the development of effective, non-surgical approaches for treating type 2 diabetes and obesity, is pleased to provide its financial results for the year ended 31 December 2011.

28 Feb 2012

TAK-875 - an emerging therapy for Type 2 diabetes

In a trial of 426 patients with Type 2 diabetes, TAK-875 reduced blood sugar below a pre-determined level in as much as 48 percent of those receiving it after 12 weeks, compared with 40 percent of those who took glimepiride, the older drug, according to findings published online by The Lancet medical journal. The research was presented in June at the American Diabetes Association’s annual meeting in San Diego.

28 Feb 2012

Strong link between BMI and asthma in Hispanic youth

Children and adolescents who are overweight or obese are more likely to have asthma than their healthy weight counterparts, according to a new Kaiser Permanente Southern California study published in the online edition of Obesity. The study, which included more than 681,000 children between ages 6 and 19, found that the association between asthma and body mass index varied by race and ethnicity.

28 Feb 2012

TAK-875 as effective as glimepiride in treating type 2 diabetes

TAK-875, a new treatment for type 2 diabetes, improves blood sugar control and is equally effective as glimepiride, but has a significantly lower risk of creating a dangerous drop in blood sugar, called hypoglycemia, according to a new study.

27 Feb 2012